Biotronik releases new ICD to treat heart failure

A new implantable cardioverter defibrillator (ICD) designed to treat heart failure patients is now available in the U.S.

The Inventra HF-T, manufactured by Biotronik, an endovascular medical technology company based in Berlin, delivers 42 joules (J) in a single shock, which helps convert dangerous arrhythmias to a normal heart rhythm.

The system offers dual-chamber diagnostics with one specialized defibrillator lead that can help patients with minimized risk and expense, the company said in a statement.

“For an increasing number of patients–specifically those with larger cardiac anatomy and lower ejection fraction–a shock that is higher than the standard 36-37 J may be needed to convert irregular arrhythmia,” said Mark Mascarenhas, MD, an electrophysiologist at Jersey Shore University Medical Center in Neptune, New Jersey. “The sooner an effective shock can be delivered, the likelihood of survival increases for these patients. For such patients, a CRT-D that delivers ultra-high energy on the first shock has a higher chance of converting the irregular arrhythmia. With the availability of Inventra HF-T, more heart failure patients will be able to receive 42 J energy delivered upon the first shock and, hence, receive life-saving therapy.”